Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 3 months ago Source:  Radcliffe Cardiology
While social determinants of health (SDOH) are known to influence outcomes in acquired cardiovascular diseases, their impact on conditions with a strong genetic basis, such as hypertrophic cardiomyopathy (HCM), has been less clear.² A new study using data from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) suggests that area-based social factors are independently associated with adverse… View more
Added: 9 months ago Source:  Radcliffe CVRM
AUTHOR: Liam ONeillWhile elevated systolic blood pressure variability (SBPV) is a known risk factor for adverse health outcomes, new research published in the European Heart Journal suggests that the change in SBPV over time is also a critical prognostic indicator. The study found that an increase in visit-to-visit SBPV over a 10-year period was significantly associated with a higher risk of… View more
Author(s): Dipti Itchhaporia , Valentin Fuster Added: 1 year ago
In this exclusive episode of the "Innovations in Cardiology" podcast series, host Dr Dipti Itchhaporia, past president of the American College of Cardiology, delves into the latest advancements in cardiovascular health. She is joined by Dr Valentin Fuster, a pioneer in the field, who shares invaluable insights into the impact of biological ageing, the connection between the heart and brain, and… View more
Added: 7 months ago Source:  Radcliffe Cardiology
Treatment with volenrelaxin, a long-acting human relaxin analogue, was associated with worsening congestion in patients with recently decompensated heart failure with preserved ejection fraction (HFpEF), leading to the early termination of the phase 2 RELAXIN-LA trial.¹ Despite this, the lowest dose of the drug did show an improvement in the study's primary endpoint.Relaxin is a peptide hormone… View more
Added: 5 months ago Source:  Radcliffe Cardiology
Observational studies have long suggested that women who experience hypertensive disorders of pregnancy (HDP) face a greater risk of cardiovascular disease (CVD) later in life. A new genetic epidemiological study has explored whether this association is causal, using Mendelian randomization (MR) to investigate the genetic underpinnings of this risk. The findings suggest a genetic predisposition… View more
Author(s): Mirvat Alasnag , Khaled Al-Shaibi Added: 1 year ago
ESC Congress 24 – Day 2 of the ESC Congress 2024 was packed with important data for cardiovascular practice.Interventional experts DrMirvat Alasnagand DrKhaled Al-Shaibi(King Fahd Armed Forces Hospital, SA) joined us to summarise the key take-home messages from hot line trials presented on day.Day 2 Highlights:00:24-03:02: NOTION-3: Percutaneous coronary intervention in patients undergoing… View more
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 year ago
Unpack ACC.25's Top Trials with View from the Thoraxcenter!Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC 2025.In this thought-provoking ACC 2025 wrap-up, delve into the nuances of the most impactful trials, gaining insights into their implications for current practice and future research directions.00:36 -… View more
Added: 9 months ago Source:  ESC Congress 2025 Scientific Programme
Ten hot line sessions have been announced for ESC Congress 2025.The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid.Access the full programme here.Hot Line 1Friday 29th August, 11:00am – 12:00pm (CEST)POTCAST – a Randomized Controlled Trial of Arrhythmia prevention using targeted plasma potassium levels in ICD Patients – Presented by Christian… View more